Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.
Biogen/Eisai’s AD drug candidate, BAN2401 has shown positive results in a late-stage clinical study. This is the first late-stage anti-amyloid antibody (BAN2401) study to successfully achieve statistically significant results at 18 months. Login to read the full article.